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Identity 
Other names: FBLN, FIBL1 
HGNC (Hugo): FBLN1 
Location: 22q13.31 
Local order: Orientation: plus strand. 
Note: Fibulin-1 is an extracellular matrix (ECM) and 
blood glycoprotein. It is a member of the fibulin 
glycoprotein family which includes 6 proteins thought 
to function as bridges in the organization of ECM 
supramolecular structures (Argraves et al., 1990; Timpl 
et al., 2003). 
DNA/RNA 
Description 
Sequence length: 97, 71 kb, 20 exons, maximum  
exon length: 818, minimun exon length: 50. Number of 
SNPs 1038. Four splice variants have been identified 
which differ in the 3' end and encode different isoforms 
(A, B, C and D) (Pan et al., 1999). 
Variant D: This variant is considered the canonic 
transcript form: 2947 bp; 
- Including exons 18, 19 and 20; 
- Lacking exons 15 and 16. 
Variant B: 2530 bp; 
- Including exon 17; 
- Lacking exons, 16, 18, 19 and 20. 
Variant A: 2350bp; 
- Including exon 15; 
- Lackings exons 16 to 20. 
Variant C: 2313bp; 
- Including exon 16; 






















Position Length Description 
36-76 41 Anaphylatoxin-like 1 
77-111 35 Anaphylatoxin-like 2 
112-144 33 Anaphylatoxin-like 3 
176-215 40 EGF-like 1 
216-261 46 EGF-like 2; calcium-binding 
262-307 46 EGF-like 3; calcium-binding 
308-355 48 EGF-like 4; calcium-binding 
356-398 43 EGF-like 5; calcium-binding 
399-440 42 EGF-like 6; calcium-binding 
441-480 40 EGF-like 7; calcium-binding 
481-524 44 EGF-like 8; calcium-binding 
525-578 54 EGF-like 9; calcium-binding 
Glycosylation 98; 535; 539 
Disulfide 
bond 
36↔61; 37↔68; 50↔69; 78↔109; 91↔110; 112↔136; 113↔143; 126↔144; 180↔190; 
186↔199; 201↔214; 220↔233; 227↔242; 248↔260; 266↔279; 273↔288; 294↔306; 
312↔325; 319↔334; 341↔354; 360↔373; 367↔382; 384↔397; 403↔415; 411↔424; 
426↔439; 445↔454; 450↔463; 465↔479; 485↔498; 494↔507; 509↔523; 529↔542; 
536↔551; 556↔577 
 
      Amino acid modifications (UNIPROT)  
 
Fibulin-1 homomultimerizes and interacts with various 
ECM components such as fibronectin (FN) (Balbona et 
al., 1992), laminin subunits alpha-1 and apha-2 
(LAMA1 and LAMA2), nidogen (NID), Aggrecan core 
protein (ACAN), versican core protein (CSPG2) and 
type IV collagen proteins (Timpl et al., 2003). Fibul n-
1 also interacts with amyloid beta A4 (APP) (Ohsawa 
et al., 2001), insulin-like growth factor-binding protein 
9 (NOV) (Perbal et al., 1999), fibrinogen (FGB) (Tran 
et al., 1995), and human papillomavirus (HPV) type 16, 
18, 31 proteins (Du et al., 2002). 










Secreted, extracellular space, extracellular matrix. 
Function 
Fibulin-1 is incorporated into FN-containing matrix 
fibers. It plays a role in cell adhesion and migration 
along protein fibers within the ECM and is important 
for certain developmental processes. Fibulin-1 
contributes to the supramolecular organization of ECM 
architecture, in particular to that of the basement 
membrane. It is implicated in cellular transformation 
and tumor invasion, and can behave both as an 
oncosuppressor and oncogene depending on tissue 
environment. It also plays a role in hemostasis and
thrombosis owing to its ability to bind fibrinogen and 
incorporate into clots and plays a significant role in 
modulating the neurotrophic activities of APP, 
particularly soluble APP (Timpl et al., 2003). 
Homology 
Paralogs: latent-transforming growth factor beta-
binding protein 1 (LTBP1), LTBP2, LTBP3, LTBP4, 
fibrillin-1 (FBN1), FBN2, FBN3, FBLN5, fibulin-2 
(FBLN2), epidermal growth factor-like protein 6 
(EGFL6), nephronectin (NPNT), EGF-containing 
fibulin-like extracellular matrix protein 2 (EFEMP2), 
Von Willebrand factor C (VWCE). 
Mutations 
Note 
- Location: exon 19 (acceptor splice site)  
- Substitution: G-A  





Several studies have reported that fibulin-1 is 
overexpressed in various human neoplasias and it is 
implicated in processes such as invasion, motility, and 
in vivo tumor growth (Qing et al., 1997; Twal et al., 
2001; Du et al., 2002; Moll et al., 2002; Greene et al., 
2003). Fibulin-1 inhibits in vitro adhesion and motility 
of various carcinoma cell lines (Twal et al., 2001). 
Breast cancer 
Prognosis 
Fibulin-1 was found aberrantly expressed in ~35% of 
528 human primary breast cancers. Its expression is 
associated with improved survival in patients with 
lymphoid infiltrate at the tumor site (Pupa et al.,2004), 
suggesting a possible involvement in triggering a 
protective antitumor immune response. Fibulin-1 
induces specific B- and T-cell-mediated responses in 
breast cancer patients (Forti et al., 2002; Pupa et l., 
2004). Its overexpression can serve as a tool for early 
detection of breast cancer (Pupa et al., 2002) and acts to 
promote breast cancer cell survival during doxorubicin 
treatment (Pupa et al., 2007). In a series of 36 primary 
breast carcinomas, the expression of mature fibulin-1 
polypeptide (100 kDa) did not correlate with estrogen 
receptor-alpha (ERalpha) or progesterone receptor (PR)
levels, whereas a positive correlation was found 
between fibulin-1 processing (50 kDa fragment) and 
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Ovarian cancer 
Disease 
The molecular mechanisms involved in ovarian 
carcinogenesis remain unclear, but growing evidence 
indicates that estrogens promote progression of ovarian 
cancer and increase expression levels of some secreted 
proteins. Differential overexpression of ERalpha versus 
ERbeta has been demonstrated during ovarian 
carcinogenesis (Clinton et al., 1996; Moll et al., 2002), 
suggesting that estrogen-induced proteins, including 
fibulin-1, may act as ovarian tumor-promoting agents. 
In ovarian tissues and cancer cell lines, fibulin-1C and -
1D are the predominant forms, whereas fibulin-1A and
-1B are weakly expressed. An increased fibulin-1C:-D 
mRNA ratio in ovarian cancer cells as compared to that
in normal ovaries has been observed, suggesting that 
the C variant is the main one involved in ovarian 
carcinogenesis. Fibulin-1C overexpression might 
provide a clue in understanding the putative role of 
estrogens in ERalpha-promoted ovarian tumor 
progression (Moll et al., 2002). 
Synpolydactyly 
Disease 
Synpolydactyly is a rare genetic disorder characterized 
by malformations in the hands and feet, with 
abnormalities including increased finger and toe 
numbers and fusion of digits into a single digit. 
Molecular analysis of the reciprocal chromosomal 
translocation t(12;22)(p11.2;q13.3) cosegregating with 
a complex type of synpolydactyly indicated 
involvement of an alternatively spliced exon of the 
fibulin-1 gene (FBLN1 located in 22q13.3). 
Investigation of the possible functional involvement of 
the fibulin-1 protein in the observed phenotype showed 
that fibulin-1 is expressed in the ECM in association 
with the digits in the developing limb (Debeer et al.,
2002). Thus, t(12;22) might result in haplo-
insufficiency of the fibulin-1D variant, leading to the 
observed limb malformations. 
Bernard-Soulier syndrome 
Disease 
Bernard-Soulier syndrome is an autosomic-dominant 
disease that causes alterations of the 
megakaryocyte/platelet lineage and is characterized by 
bleeding tendency, giant blood platelets and low 
platelet counts. An unexpected mutation in the splice 
acceptor site of fibulin-1 exon 19 was found in affected 
individuals of the Israeli Fechtner family. In all 
affected individuals from eight families, expression f 
fibulin-1 variant D was inhibited by putative antisense 
RNA (Lanza, 2006), raising the possibility that these 
autosomal-dominant giant platelet syndromes are 





Placental dysplasia is a rare human placental disorder 
in which the placenta is enlarged and contains cystic 
villi and dilated vasculature. A significant correlation 
was observed between fibulin-1 gene overexpression 
and murine placental overgrowth (Singh et al., 2006), 
suggesting that the gene and its product have a 
functional role in placenta development. 
Morphogenesis of neural crest-derived 
structures 
Disease 
A significant negative correlation between fibulin-1 
gene expression and some morphogenic anomalies of 
neural crest-derived structures in mice has been 
reported (Cooley et al., 2008). Such fibulin-1-deficient 
mice exhibit cardiac ventricular wall thinning and 
ventricular septal defects, with double outlet right 
ventricle or overriding aorta, as well as aortic arch 
arteries anomalies, hypoplasia of the thymus and 
thyroid, underdeveloped skull bones, malformations f 
cranial nerves and hemorrhagic blood vessels in the 
head and neck. The spectrum of malformations is 
consistent with a role for fibulin-1 in neural crest cell-
dependent development of these tissues. 
Acute aortic dissection 
Disease 
Acute aortic dissection (AAD) is a tear in the wall of 
the aorta that causes blood to flow between the layrs 
of the wall of the aorta and force the layers apart. AAD 
is a life-threatening condition with high mortality and a 
mostly unclear pathophysiological mechanism. 
Downregulation of fibulin-1 noted in AAD compared 
to control samples might determine a weakening of 
ECM in the aorta and/or interfere with the transmission 




Fibulin-1 deposits were found in association with 
fibrinogen in atherosclerotic lesions and in regions 
containing fresh thrombi. By contrast, fibulin-1 was not 
detected in sclerotic regions and low levels were 
associated with smooth muscle cells within and outside 
lesions (Argraves et al., 2009). 
Thrombosis 
Disease 
Thrombosis, the formation of a blood clot (thrombus) 
inside a blood vessel, obstructs blood flow through the 
circulatory system. Analyses of blood plasma revealed 
an interaction between fibulin-1 and fibrinogen (Tran et 
al., 1995), pointing to potential new roles for fibulin-1 
in hemostasis as well as thrombosis. 
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Breakpoints 
Note 
Description: Translocation t(12;22)(p11.2;q13.3). 
Phenotype: Synpolydactyly. 
Analysis of a Belgian family with a complex type of
synpolydactyly (SPD2) and a t(12;22)(p11.2;q13.3) 
translocation identified the breakpoints located in the 
intron between the last 2 exons of the fibulin-1D splice 
variant isoform (exons 19, 20) and the 5' UTR of the
C12ORF2 gene. Fibroblasts derived from the patients 
displayed decreased levels of ECM-related fibulin-1D 
secreted into the culture medium, whereas levels of the 
fibulin-1C variant were normal. The findings are 
consistent with the notion that the 
t(12;22)(p11.2;q13.3) translocation results in haplo-
insufficiency of the fibulin-1D variant, leading to the 
observed limb malformations. The authors noted that
the entire fibulin-1 gene is deleted in the chromosome 
22q13.3 deletion syndrome (Debeer et al., 2002). 
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